Spyre Therapeutics Inc's stock surged 5.51% during intraday trading on Monday, following a positive analyst action from Deutsche Bank.
The investment bank raised its price target for Spyre Therapeutics to $55 from $45, signaling increased confidence in the company's future performance and likely contributing to the stock's upward movement.